NCT00194818View on ClinicalTrials.gov

Asacol Dosing Study for Active Ulcerative Colitis

PHASE4CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Ulcerative Colitis
Interventions
DRUG

Asacol (mesalamine)

Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.

Trial Locations (1)

98195

University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

Procter and Gamble

INDUSTRY

lead

University of Washington

OTHER

NCT00194818 - Asacol Dosing Study for Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter